Finding new ways to improve survival from a dangerous bacterial infection.
Official title: Improving survival from Burkholderia pseudomallei and other pathogenic intracellular bacteria
Funded at Bolder Biotechnology, INC. · NIH-10822404 · Data updated 2026-11-12
This study is looking for new ways to help your body fight off a dangerous germ called Burkholderia pseudomallei, which causes melioidosis, by boosting your immune system, especially in emergencies when current antibiotics might not work well.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Bolder Biotechnology, INC. NIH-funded |
| Lab location | 1 site (Boulder, United States) |
| Project start | February 1, 2024 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $295,924 |
| NIH project number | 1R43AI181293-01 |
| Project ID | NIH-10822404 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals at high risk of exposure to Burkholderia pseudomallei, such as healthcare workers and first responders in outbreak situations.
✕Less likely to help
Patients who are not at risk of exposure to Burkholderia pseudomallei or those with other unrelated health conditions may not benefit from this research.
What this research studies
This research focuses on Burkholderia pseudomallei, a highly dangerous bacterium that causes melioidosis and poses a significant threat to public health. The project aims to develop new treatments that stimulate the body's immune response, particularly through the use of interferon gamma, which can help protect against severe infections. Given that current antibiotics are often ineffective against this bacterium, the research seeks to explore innovative approaches to enhance immunity quickly, especially in emergency situations. Patients may benefit from this research if new therapies are developed that can be used in acute cases of infection.
Why it matters
Potential benefit: If successful, this research could lead to effective treatments that significantly improve survival rates for patients infected with Burkholderia pseudomallei.
How similar studies have gone: While there is ongoing research into immune response stimulation, this specific approach targeting Burkholderia pseudomallei is relatively novel and has not been extensively tested.
Where this research is happening
-
Bolder Biotechnology, INC.
Boulder, United States Active
Researchers
- Principal investigator: Cox, George Norbert — Bolder Biotechnology, INC.
- Study coordinator: Cox, George Norbert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.